Citations

Clear

1053 citation(s) found for "Andre, F".

Development of an in vivo mouse model of discogenic low back pain
Shi, Changgui , Das, Vaskar, Li, Xin , Kc, Ranjan , Qiu, Sujun , O‐Sullivan, InSug , Ripper, Richard, Kroin, Jeffrey S., Mwale, Fackson , Wallace, Atiyayein A., Zhu, Bingqian , Wijnen, André J. van , Ji, Ming-liang , Lü, Jun , Votta‐Velis, Gina , Yuan, Wen, Im, Hee‐Jeong , van Wijnen, Andre J , Zhao, Lan , Yuan, Wen

Mayo Clinic

Journal of Cellular Physiology | November 18, 2017 | Volume: 233 | Issue: 10 | Pages: 6589-6602

10.1002/jcp.26280 | PMID 29150945 Get It

Discogenic low back pain (DLBP) is extremely common and costly. Effective treatments are lacking due to DLBP's unknown pathogenesis. Currently, there are no in vivo mouse models of DLBP, which restricts research in this field. The aim of this study was to establish a reliable DLBP model in mouse that captures the pathological changes in the disc and allows longitudinal pain testing. The model was generated by puncturing the mouse lumbar discs (L4/5, L5/6, and L6/S1) and removing the nucleus pulposus using a microscalpel under the microscope. Histology, molecular pathways, and pain‐related behaviors were examined. Over 12 weeks post‐surgery, animals displayed the mechanical, heat, and cold hyperalgesia along with decreased burrowing and rearing. Histology showed progressive disc degeneration with loss of disc height, nucleus pulposus reduction, proteoglycan depletion, and annular fibrotic disorganization. Immunohistochemistry revealed a substantial increase in inflammatory mediators at 2 and 4 weeks. Nerve growth factor was upregulated from 2 weeks to the end of the experiment. Nerve fiber ingrowth was induced in the injured discs after 4 weeks. Disc‐puncture also produced an upregulation of neuropeptides in dorsal root ganglia neurons and an activation of glial cells in the spinal cord dorsal horn. These findings indicate that the cellular and structural changes in discs, as well as peripheral and central nervous system plasticity, paralleled persistent, and robust behavioral pain responses. Therefore, this mouse DLBP model could be used to investigate mechanisms underlying discogenic pain, thereby facilitating effective drug screening and development of treatments for DLBP.
ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome)
Than, Martin , Pickering, John W. , Dryden, Jeremy M., Lord, Sally J., Aldous, Sally, Allan, Kate , Ardagh, Michael, Bonning, John , Callender, Rosie, Chapman, Laura R.E., Christiansen, J., Cromhout, Andre P.J., Cullen, Louise , Deely, Joanne M., Devlin, Gerard, Ferrier, Katherine, Florkowski, Christopher M , Frampton, Christopher , George, Peter M., Hamilton, Gregory J. , Jaffe, Allan S. , Makower, R M, Matthews, Timothy James , Parsonage, William , Pelt, Niels C van, Poynton, Louise, Richards, Mark , Scott, Anthony, Simmonds, Mark, Smyth, David, Thomas, Oliver P., To, Andrew, Toit, Stephen A. Du, Troughton, Richard W. , Yates, Kim , Lord, Sarah J. , Cullen, Louise , Aitken, Stuart A. , Chapman, Laura , Jaffe, Allan S. , Kerr, Andrew Jensen , Larkin, Gregory Luke , Peacock, William Frank , Peckler, Brad , Toit, Stephen Du , Troughton, Richard W , Lord, Sarah J , Richards, Arthur M , Than, Martin , Pickering, John W

Mayo Clinic

Circulation | November 15, 2017 | Volume: 137 | Issue: 4 | Pages: 354-363

10.1161/circulationaha.117.031984 | PMID 29138293 Get It

Background: Efforts to safely reduce length of stay for emergency department patients with symptoms suggestive of acute coronary syndrome (ACS) have had mixed success. Few system-wide efforts affecting multiple hospital emergency departments have ever been evaluated. We evaluated the effectiveness of a nationwide implementation of clinical pathways for potential ACS in disparate hospitals. Methods: This was a multicenter pragmatic stepped-wedge before-and-after trial in 7 New Zealand acute care hospitals with 31 332 patients investigated for suspected ACS with serial troponin measurements. The implementation was a clinical pathway for the assessment of patients with suspected ACS that included a clinical pathway document in paper or electronic format, structured risk stratification, specified time points for electrocardiographic and serial troponin testing within 3 hours of arrival, and directions for combining risk stratification and electrocardiographic and troponin testing in an accelerated diagnostic protocol. Implementation was monitored for >4 months and compared with usual care over the preceding 6 months. The main outcome measure was the odds of discharge within 6 hours of presentation Results: There were 11 529 participants in the preimplementation phase (range, 284–3465) and 19 803 in the postimplementation phase (range, 395–5039). Overall, the mean 6-hour discharge rate increased from 8.3% (range, 2.7%–37.7%) to 18.4% (6.8%–43.8%). The odds of being discharged within 6 hours increased after clinical pathway implementation. The odds ratio was 2.4 (95% confidence interval, 2.3–2.6). In patients without ACS, the median length of hospital stays decreased by 2.9 hours (95% confidence interval, 2.4–3.4). For patients discharged within 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P =0.96). In these patients, no adverse event occurred when clinical pathways were correctly followed. Conclusions: Implementation of clinical pathways for suspected ACS reduced the length of stay and increased the proportions of patients safely discharged within 6 hours. Clinical Trial Registration: URL: https://www.anzctr.org.au/ (Australian and New Zealand Clinical Trials Registry). Unique identifier: ACTRN12617000381381.
Posology for Regenerative Therapy
Behfar, Atta , Behfar, Atta , Terzic, André

Mayo Clinic

Circulation Research | November 9, 2017 | Volume: 121 | Issue: 11 | Pages: 1213-1215

10.1161/circresaha.117.312074 | PMID 29122941 Get It

Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine
Samsonraj, Rebekah M. , Raghunath, Michael , Nurcombe, Victor , Hui, James Hoi Po , Wijnen, André J. van , Cool, Simon M. , van Wijnen, Andre J

Mayo Clinic

Stem Cells Translational Medicine | October 27, 2017 | Volume: 6 | Issue: 12 | Pages: 2173-2185

10.1002/sctm.17-0129 | PMID 29076267 Get It

Abstract Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy.
Regenerative Musculoskeletal Care: Ensuring Practice Implementation
Saris, Daniël B.F. , Windt, Tommy S. de , Vonk, Luciënne A. , Krych, Aaron J. , de Windt, Tommy S , Krych, Aaron J , Vonk, Lucienne A , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | October 16, 2017 | Volume: 103 | Issue: 1 | Pages: 50-53

10.1002/cpt.883 | PMID 29034457 Get It

Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine
Sterner, Rosalie M. , Kremer, Kimberly N. , Al‐Kali, Aref , Patnaik, Mrinal M. , Gangat, Naseema , Litzow, Mark R. , Wijnen, André J. van , Hedin, Karen E. , Kaufmann, Scott H. , van Wijnen, Andre J , Westendorf, Jennifer J.

Mayo Clinic

Oncotarget | October 12, 2017 | Volume: 8 | Issue: 55 | Pages: 94569-94579

10.18632/oncotarget.21809 | PMID 29212250 Get It

Comparison of Methods for Analyzing Human Adipose Tissue Macrophage Content
Morgan‐Bathke, Maria , Harteneck, Debra A., Jaeger, Philippa, Søndergaard, Esben , Karwoski, R., Ycaza, Ana Espinosa De, Carranza-Leon, Barbara Gisella , Faubion, William A. , Oliveira, André M. , Jensen, Michael D. , Harteneck, Debra, Karwoski, Ron, Espinosa De Ycaza, Ana, Carranza-Leon, B Gisella

Mayo Clinic

Obesity | October 6, 2017 | Volume: 25 | Issue: 12 | Pages: 2100-2107

10.1002/oby.22012 | PMID 28985040 Get It

ObjectiveThe relationship between inflammation, obesity, and adverse metabolic conditions is associated with adipose tissue macrophages (ATM). This study compared the measurements of human ATM using flow cytometry, immunohistochemistry (IHC), and real‐time polymerase chain reaction (RT‐PCR) of ATM markers.MethodsA new software program (AMCounter) was evaluated to help measure ATM using IHC, and this was compared to flow cytometry and RT‐PCR.ResultsIHC had good intraindividual reproducibility for total (CD68), proinflammatory (CD14), and anti‐inflammatory (CD206) ATM. The AMCounter improved interreader agreement and was more time efficient. Flow cytometry had acceptable intraindividual reproducibility for the percentage of CD68+ cells that were CD14+ or CD206+, but not for ATMs per gram of tissue. ATMs per gram of tissue was much greater using IHC than flow cytometry. The flow cytometry and IHC measures of ATM from the same biopsies were not correlated. There were statistically significant correlations between RT‐PCR CD68 and IHC CD68, CD14, and CD206 ATMs per 100 adipocytes. Also of interest were statistically significant correlations between RT‐PCR CD68 and IHC CD68, CD14, and adipose flow cytometry measures of CD68+, CD68+/CD14+, and CD68+/CD206+ ATMs per gram of tissue.ConclusionsThe AMCounter software helps provide reproducible and efficient measures of IHC ATMs. Flow cytometry, IHC, and RT‐PCR measures of adipose inflammation provide somewhat different information.
Immobilization of vitronectin‐binding heparan sulfates onto surfaces to support human pluripotent stem cells
Yap, Lynn , Murali, Sadasivam, Bhakta, Gajadhar, Chen, Allen Kuan‐Liang, Sim, Lyn Chiin, Lim, Yu Ming , Goh, James Cho‐Hong , Oh, Steve , Choo, Andre , Wijnen, André J. van , Robinson, David E., Whittle, Jason D. , Short, Robert D. , Nurcombe, Victor , Cool, Simon M. , van Wijnen, Andre J , Titmarsh, Drew M. , Bardor, Muriel , Birch, William R.

Mayo Clinic

Journal of Biomedical Materials Research Part B: Applied Biomaterials | September 20, 2017 | Volume: 106 | Issue: 5 | Pages: 1887-1896

10.1002/jbm.b.33999 | PMID 28941021 Get It

AbstractFunctionalizing medical devices with polypeptides to enhance their performance has become important for improved clinical success. The extracellular matrix (ECM) adhesion protein vitronectin (VN) is an effective coating, although the chemistry used to attach VN often reduces its bioactivity. In vivo, VN binds the ECM in a sequence‐dependent manner with heparan sulfate (HS) glycosaminoglycans. We reasoned therefore that sequence‐based affinity chromatography could be used to isolate a VN‐binding HS fraction (HS9) for use as a coating material to capture VN onto implant surfaces. Binding avidity and specificity of HS9 were confirmed by enzyme‐linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR)‐based assays. Plasma polymerization of allylamine (AA) to tissue culture‐treated polystyrene (TCPS) was then used to capture and present HS9 as determined by radiolabeling and ELISA. HS9‐coated TCPS avidly bound VN, and this layered surface supported the robust attachment, expansion, and maintenance of human pluripotent stem cells. Compositional analysis demonstrated that 6‐O‐ and N‐sulfation, as well as lengths greater than three disaccharide units (dp6) are critical for VN binding to HS‐coated surfaces. Importantly, HS9 coating reduced the threshold concentration of VN required to create an optimally bioactive surface for pluripotent stem cells. We conclude that affinity‐purified heparan sugars are able to coat materials to efficiently bind adhesive factors for biomedical applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1887–1896, 2018.
Animal models for studying the etiology and treatment of low back pain
Shi, Changgui , Qiu, Sujun , Riester, Scott M. , Das, Vaskar, Zhu, Bingqian , Wallace, Atiyayein A., Wijnen, André J. van , Mwale, Fackson , Iatridis, James C. , Sakai, Daisuke , Votta‐Velis, Gina , Yuan, Wen, Im, Hee‐Jeong , van Wijnen, Andre J , Iatridis, James C , Yuan, Wen

Mayo Clinic

Journal of Orthopaedic Research | September 18, 2017 | Volume: 36 | Issue: 5 | Pages: 1305-1312

10.1002/jor.23741 | PMID 28921656 Get It

ABSTRACTChronic low back pain is a major cause of disability and health care costs. Effective treatments are inadequate for many patients. Animal models are essential to further understanding of the pain mechanism and testing potential therapies. Currently, a number of preclinical models have been developed attempting to mimic aspects of clinical conditions that contribute to low back pain (LBP). This review focused on describing these animal models and the main behavioral tests for assessing pain in each model. Animal models of LBP can be divided into the following five categories: Discogenic LBP, radicular back pain, facet joint osteoarthritis back pain, muscle‐induced LBP, and spontaneous occurring LBP models. These models are important not only for enhancing our knowledge of how LBP is generated, but also for the development of novel therapeutic regimens to treat LBP in patients. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1305–1312, 2018.
Anatomical features of the cervical spinal canal in Chiari I deformity with presyrinx: A case-control study
Gadde, Judith A. , Pomeraniec, I. Jonathan , Bakke, S. J., Frič, Radek , Ksendzovsky, Alexander , Jane, John A. , Schwartz, Erin Simon , Haughton, Victor M. , Liebo, Greta B. , Shah, Vinil N. , Ringstad, Geir André

Mayo Clinic

The Neuroradiology Journal | September 15, 2017 | Volume: 30 | Issue: 5 | Pages: 405-409

10.1177/1971400917718842 | PMID 28691569 Get It

Purpose The relationship between syringomyelia and presyrinx, characterized by edema in the spinal cord, has not been firmly established. Patients with syringomyelia have abnormal spinal canal tapering that alters cerebrospinal fluid flow dynamics, but taper ratios in presyrinx have never been reported. We tested the hypothesis that presyrinx patients have abnormal spinal canal tapering. Materials and methods At six medical institutions, investigators searched the PACS system for patients with Chiari I and spinal cord edema unassociated with tumor, trauma, or other evident cause. In each case taper ratios were calculated for C1 to C4 and C4 to C7. In two age- and gender-matched control groups, Chiari I patients with no syringomyelia and patients with normal MR scans, the same measurements were made. Differences between groups were tested for statistical significance with t tests. Results The study enrolled 21 presyrinx patients and equal numbers of matched Chiari I and normal controls. C4 to C7 taper ratios were positive and steeper in presyrinx patients than in the normal controls ( p = 0.04). The upper cervical spine, C1 to C4, tapered negatively in cases and controls without significant differences between the groups. The difference in degree of tonsillar herniation was statistically significant between presyrinx patients and Chiari I controls ( p = 0.01). Conclusions Presyrinx patients have greater than normal positive tapering in the lower cervical spine and greater degree of tonsillar herniation than the controls.